Business Wire

BYD-AUTO

21.11.2023 02:00:47 CET | Business Wire | Press release

Share
BYD Showcases Full Lineup of New Energy Vehicles at the 21st Guangzhou International Automobile Exhibition

BYD, the world’s leading manufacturer of new energy vehicles, showcased its full lineup of vehicles at the 21st Guangzhou International Automobile Exhibition from November 17th to 26th. BYD featured the global debut of the e⁴ concept car, the release of the Supercar Platform, and the unveiling of the new pure electric SUV—the BYD Sea Lion 07 EV*.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120172380/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New concept car of Yangwang (Photo: Business Wire)

Yangwang Unveiled a New e⁴ Concept Car and Supercar Platform

BYD's premium sub-brand Yangwang dazzled with the debut of its latest e⁴ concept car, supercar platform, and brought U8 and U9 to the auto show. The e⁴ concept car by Yangwang lacked traditional steering gear and braking mechanisms. It employed a three-in-one technology for driving, braking, and steering, eliminating the need for conventional mechanical systems. Earlier this year, Yangwang introduced the exclusive Yangwang Architecture for high-end new energy vehicles. The Supercar Platform under this architecture made its official debut, marking Yangwang's transition from the wilderness to the racetrack with cutting-edge technology. At the exhibition, the interior of the Yangwang U9 was unveiled for the first time, showcasing a cockpit that exuded both technological sophistication and sportiness.

Sea Lion 07 EV*: A New Member of the BYD Ocean Series

BYD Ocean Series unveiled its first mid-sized pure electric SUV, the Sea Lion 07 EV*, at the exhibition. Embracing the 'Ocean Aesthetics' design philosophy, it utilized rear-wheel/four-wheel drive architecture, equipped with CTB technology and iTAC intelligent torque control technology. Additionally, it featured front double-wishbone and rear five-link independent suspension, along with the BYD DiSus Intelligent Body Control System. Currently, the Ocean Series boasts several popular models such as the Dolphin, Seal, establishing a robust Ocean Series IP. In the future, the Ocean Series would consolidate SUV models under the intellectual property of Sea Lion* and sedan models under the intellectual property of Seal.

Denza D9 PREMIER (inaugural edition with four seats) Showcased its Intelligent Configurations

Denza, another high-end sub-brand under BYD's diversified brand matrix, presented the D9 PREMIER (inaugural edition with four seats) along with several cutting-edge technologies. The exterior of D9 PREMIER (inaugural edition with four seats) adopted a galaxy dual-tone body, and the interior featured the application of intangible cultural heritage gilding techniques. The cabin was equipped with 22 DEVIALET audio speakers and a premier intelligent customized cockpit, including an 8-inch armrest screen.

In December, high-speed NOA (Navigate on Autopilot) will be rolled out to consumers, followed by the gradual release of urban NOA in Q1 of next year. High-speed NOA-enabled vehicles will be delivered to consumers in December. Additionally, features such as Sentry Mode, Light Map Mode, and Commute Mode will progressively roll out next year.

FANGCHENGBAO and the Stunning BAO 5

BYD's professional personalized sub-brand FANGCHENGBAO also brought its BAO 5 to the exhibition. The BAO 5, which was just launched last week, positioned itself as a "Super Hybrid Hardcore SUV" starting at 289,800 RMB and was equipped with BYD's core technologies such as DMO and DiSus-P. BAO 5 used the ultra-safe blade battery, which adopted a 5-layer protection structure and was shielded by a ring-type double protection system.

BYD had a total of 4 booths at the 21st Guangzhou International Automobile Exhibition, which continued until November 26th. Various of BYD’s hardcore technologies, including the Dual Mode Off-road (DMO) Super Hybrid Platform, BYD DiSus Intelligent Body Control System, and e⁴ Platform also made appearances by some display platforms at this exhibition. BYD demonstrated its pioneer technology and leading advancements, contributing to helping cool the earth by 1℃.

(The product name with the "*" mark in this press release is a translation from the Chinese product name and is currently only applicable for the expressions of models launched in China.)

About BYD

BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.

For more information, please visit www.bydglobal.com.

About BYD Auto

Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, and electronic controllers. It has witnessed in recent years significant technological advancements, including the Blade Battery, DM-i Super Hybrid Technology, e Platform 3.0, CTB Technology, e⁴ Platform, BYD DiSus Intelligent Body Control System, and DMO super hybrid system. The company is the world's first carmaker to stop the production of fossil-fueled vehicles on the EV shift and has remained top of new energy passenger vehicle sales in China for 10 years in a row.

For more information, please visit www.byd.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120172380/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye